Skip to main content
. 2024 May 3;15:1378010. doi: 10.3389/fphar.2024.1378010

FIGURE 1.

FIGURE 1

The number of 14 reported cardiovascular adverse events per year after marketing of antibody-drug conjugates (ADCs) in 14 narrow SMQ categories. Note: The blue line represents the eight antibody drug conjugates related to our research. In this figure shows the reported number of cardiovascular events associated with ADCs over time, from 2004 to the second quarter of 2023.